Skip to main content

Monitoring Trends in HIV Prevention Research Funding

Study Status:
Ongoing
Collaborators:
HIV Vaccines and Microbicides Resource Tracking Working Group; AVAC: Global Advocacy for HIV Prevention; International Partnership for Microbicides (IPM); Joint United Nations Programme on HIV/AIDS (UNAIDS)


This ongoing collaborative study by the HIV Vaccines and Microbicides Resource Tracking Working Group provides data on HIV vaccine R&D funding trends, which can enable a systematic monitoring of investment in new HIV-prevention strategies and the identification of important new trends.

 Study Description

The HIV Vaccines and Microbicides Resource Tracking Working Group was founded in 2004 to collect data on the resources dedicated to the development of new biomedical tools for HIV prevention in order to provide a better understanding of the trends in such funding. The Working Group is a collaboration between AVAC: Global Advocacy for HIV Prevention, the International AIDS Vaccine Initiative (IAVI), the International Partnership for Microbicides (IPM) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Funding data assembled by the Working Group dating back to 2000 has enabled a systematic monitoring of investment in new HIV-prevention strategies and the identification of new trends in that area.

The most recent report, “Investing to End the AIDS Epidemic: A new Era for HIV Prevention Research and Development,” (PDF) shows that funding for HIV vaccine R&D totaled $845 million in 2011, down 2% from US$859 million in 2010. In 2011, $702 million (83%) of HIV vaccine R&D funding came from the public sector, $113 million (13%) came from the philanthropic sector and $30 million (4%) came from the commercial sector.

The United States government remained the largest donor, despite a decrease in its contributions accounted for in part by the end of domestic stimulus funding. Further, funding from European public sector agencies dropped significantly. The overall decline in funding was offset somewhat by the contributions of new philanthropic supporters. Estimates of commercial funding, meanwhile, remained level. The HIV vaccine field has produced an abundance of promising data in recent years. But, given the long-term nature of HIV vaccine development, continued progress will depend on flexible and sustained investments in research and development.

Partner Sites
HIV Vaccines and Microbicides Resource Tracking Working Group www.hivresourcetracking.org  
AVAC: Global Advocacy for HIV Prevention www.avac.org
International Partnership for Microbicides (IPM) http://www.ipmglobal.org/
Joint United Nations Programme on HIV/AIDS (UNAIDS) http://www.unaids.org